ML19221B300
| ML19221B300 | |
| Person / Time | |
|---|---|
| Site: | 11006349 |
| Issue date: | 08/07/2019 |
| From: | Peter Habighorst NRC/OIP |
| To: | Ionta G Cambridge Isotope Labs |
| Savoy J | |
| References | |
| Download: ML19221B300 (7) | |
Text
United States of America Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or
production or utilization facilities listed below, subject to the terms and conditions herein.
NRC LICENSE NO.:Page 1 of 7 NRC DOCKET NO.:
LICENSE EXPIRES:March 31, 2024 Nuclear Regulatory CommissionWashington , D.C. 20555 EXPORT LICENSE Cambridge Isotope Laboratories, Inc.
50 Fontage Road Andover, MA 01810 LICENSEE ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
OTHER U.S. PARTY(IES) TO EXPORT Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic EnergyAct of 1954, as amended, and the Energy Reorganization Act of 1974.This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of
THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVENAME AND TITLE:
DATE OF ISSUANCE:
APPLICANT'S
REFERENCE:
Appl Dated ULTIMATE DESTINATION:
IndiaDESCRIPTION OF MATERIAL(S) OR FACILITY(IES)
Peter J. Habighorst, Acting Deputy Director Office of International Programs EXPORT LICENSE Attn: Gary Ionta QUANTITY(IES)
SIGNATURE: 10,000 kilograms See following page(s)
See following page(s)
Cambridge Isotope Laboratories, Inc.
50 Frontage Road Andover, MA 01810 (supplier/distributors)
Deuterium in the form of deuterium oxide, deuterium gas, and other compounds.
XMAT448 Page 2 of 7 ULTIMATE CONSIGNEE (S) IN FOREIGN COUNTRY (IES):
1.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
2.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
3.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
4.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
5.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
6.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
7.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
8.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 3 of 7 ULTIMATE CONSIGNEE (S) IN FOREIGN COUNTRY (IES):
9.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
10.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
11.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
12.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
13.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
14.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
15.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
16.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 4 of 7 ULTIMATE CONSIGNEE (S) IN FOREIGN COUNTRY (IES):
17.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
18.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
19.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
20.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
21.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
22.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
23.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
24.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 5 of 7ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
25.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
26.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
27.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
28.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
29.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
30.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
31.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT448 Page 6 of 7INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): 1.2.3.4.5.6.7.
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
(for distribution to ultimate consignees)
XMAT448 Page 7 of 7 INTERMEDIATE CONSIGNEE (S) IN FOREIGN COUNTRY (IES):
8.(for distribution to ultimate consignees)
9.(for distribution to ultimate consignees)
10.(for distribution to ultimate consignees)
11.(for distribution to ultimate consignees)
12.(for distribution to ultimate consignees)
13.(for distribution to ultimate consignees)
14.(for distribution to ultimate consignees)